Search the web
Sign In
New User? Sign Up
PozHealth
? Already a member? Sign in to Yahoo!

Yahoo! Groups Tips

Did you know...
Real people. Real stories. See how Yahoo! Groups impacts members worldwide.

Best of Y! Groups

   Check them out and nominate your group.
Having problems with message search? Fill out this form to ensure your group is one of the first to be migrated to the new message search system.

Messages

  Messages Help
Advanced
Messages 2134 - 2163 of 31345   Newest  |  < Newer  |  Older >  |  Oldest
Messages: Show Message Summaries   (Group by Topic) Sort by Date v  
#2163 From: lipodystrophy@yahoogroups.com
Date: Sat Mar 1, 2003 8:41 am
Subject: Poll results for lipodystrophy
lipodystrophy@yahoogroups.com
Send Email Send Email
 
The following lipodystrophy poll is now closed.  Here are the
final results:


POLL QUESTION: Should the makers of Zerit (D4T)
Bristol-Myers Squibb (www.bms.com) be
required by the FDA to mention the
higher risk for lipoatrophy and facial
wasting in Zerit's product insert?

CHOICES AND RESULTS
- No, 0 votes, 0.00%
- We do not know if Zerit causes that problem, 0 votes, 0.00%
- I do not know, 0 votes, 0.00%
- Yes, 11 votes, 100.00%



For more information about this group, please visit
http://groups.yahoo.com/group/lipodystrophy

For help with Yahoo! Groups, please visit
http://help.yahoo.com/help/us/groups/

#2162 From: pozbod <pozbod@...>
Date: Fri Feb 28, 2003 4:03 pm
Subject: Off topic, anal lesions
johnftl59
Offline Offline
Send Email Send Email
 
I would have to say that HPV is such a vital concern for men and women
living with HIV, that although it is "off topic," any opportunity to
make people think of this is warranted.  IMHO, not enough physicians
are paying attention to anal cancer.  I have little to add to Jeff's
excellent note.

I would like to share my perspective as a pathologist.
PAP smears are probably helpful, but not enough.  The standards for
diagnosis are all really designed for uterine cervix, and there are 50
years of good data as background.  Changes seen in the anus may not be
identical, and interpretations are difficult.
Actual examination of the anus by a proctologist may be more effective
than general screening.

In any case, you can't just wait for problems.  Each of us should
discuss this with his/her HIV specialist, and arrange for periodic
check ups.

JB


On Friday, Feb 28, 2003, at 10:47 US/Eastern,
lipodystrophy@yahoogroups.com wrote:

> I had one done by Dr Ford Kinder in Miami. He went to a two day
> seminar on
> this topic. The main problem is that more than 60 % of the time the
> results
> come back inconclusive. And most of us are poz to HPV, which makes us
> have a
> much greater risk of anal cancer. Jeff Taylor is sitting in a NHI
> committee
> that deals with research in this area (Jeff, are you there? could you
> add
> anything else for us?)

#2161 From: <mtlmuscle@...>
Date: Fri Feb 28, 2003 3:00 pm
Subject: [Fwd: Re: [lipodystrophy] Re: Oxandrin and Lipo]
muscmtl
Offline Offline
Send Email Send Email
 
This study did not include HIV poz men but only older men with visceral fat
deposits. Because of this, it is very hard for me to even consider the fact that
their findings might apply to HIV drug related fat problems. Still, one very
nice avenue for a new study where only hiv poz patients (with aids med) would be
included. This has yet to be done; knowing the amount of money that poz people
would invest in such a therapy, one wonders why the big Drug companies are not
doing such research.

Steve
In a message dated 2/28/03 7:13:02 AM Central Standard Time, mtlmuscle@... writes:

PS: J of Obesity study : I cannot find this journal or the article that was mentioned. If you could provide the tile I would gladly read the article with my epidmiologist brain.

Steve


Steve: This one shows decreases in sub cutaneous fat (not what we want) and a trend towards decreases in visceral  fat.

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.Int J Obes Relat Metab Disord. 1995 Sep;19(9):614-24.
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.
OBJECTIVE:
To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means. DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL). MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters. RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters. CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat.Publication Types:



Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health
























#2160 From: PoWeRTX@...
Date: Fri Feb 28, 2003 9:57 am
Subject: Facial Filler Video
PoWeRTX@...
Send Email Send Email
 

Click here: CNN.com - Video/Audio



Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health


#2159 From: PoWeRTX@...
Date: Fri Feb 28, 2003 9:48 am
Subject: Re: [lipodystrophy] Re: Oxandrin and Lipo
PoWeRTX@...
Send Email Send Email
 
In a message dated 2/28/03 7:13:02 AM Central Standard Time, mtlmuscle@... writes:

PS: J of Obesity study : I cannot find this journal or the article that was mentioned. If you could provide the tile I would gladly read the article with my epidmiologist brain.

Steve


Steve: This one shows decreases in sub cutaneous fat (not what we want) and a trend towards decreases in visceral  fat.

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.Int J Obes Relat Metab Disord. 1995 Sep;19(9):614-24.
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.
OBJECTIVE:
To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means. DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL). MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters. RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters. CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat.Publication Types:



Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health
























#2158 From: <mtlmuscle@...>
Date: Fri Feb 28, 2003 1:11 pm
Subject: Re: Oxandrin and Lipo
muscmtl
Offline Offline
Send Email Send Email
 
Wow, the last posting on oxandrolone and GH is amazing. I feel like I am living
on another planet since GH will never be prescribed to me. All the deca that was
prescribed was done quite illegally threw the son of a doctor I know, otherwise
I would have never even had been able to try deca.

Reading all these wonderful details on GH just makes me wonder how you poeple
even come close to having someone actually prescribe that stuff. Living in
Montreal, I can assure you that in order to have the tiny bit of steroids
prescribed, one has to be on his death bed.

Still, thanks you for that very informative info.

PS: J of Obesity study : I cannot find this journal or the article that was
mentioned. If you could provide the tile I would gladly read the article with my
epidmiologist brain.

Steve

#2157 From: legnsac@...
Date: Fri Feb 28, 2003 8:01 am
Subject: unscribe
legnsac@...
Send Email Send Email
 
#2156 From: GetWell@...
Date: Fri Feb 28, 2003 7:46 am
Subject: Re: [lipodystrophy] Re: Oxandrin and Lipo
getwell5
Offline Offline
Send Email Send Email
 
In a message dated 2/27/03 1:16:45 PM Eastern Standard Time, PoWeRTX writes:


In a message dated 2/27/03 12:07:55 PM Central Standard Time, mmooney@... writes:


The best combo to decrease fat, visceral or other (subcutaneous) fat is GH, an oral steroid like Oxandrin, Winstrol (which costs less) or Anadrol, and Metformin (MET, if there is no chance of lactic acidosis). There should be a base of testosterone, and perhaps nandrolone for anabolic effect, but they too can decrease subcutaneous fat. Take glutamine too, as it helps improve insulin sensitivity. Glutamine appears to enhance fat loss in two studies of rats, and in my personal experience.

 
Michael Mooney



I would rather see more work on Avandia (rosiglitazone) and Actos (pioglitazone) than Glucophage (Metformin). Metformin seems to be anorexic (causes weight loss), cause hypoglycemia, cause diarrhea, and may cause lactic acidosis (which we have not seen in studies yet) whereas Avandia and Actos do not. These insulin sensitizers may also help keep glucose down when using Serostim (Serostim may worsen insulin resistance). I am also very concerned about the use of oral anabolic steroids by those with pre-existing liver disease, Hep C and high liver enzymes.

Nelson Vergel


There is actually a warning on the package insert stating that Metformin may cause lactic acidosis, so I'm sure it's been studied.  My own logic would then tell me that if a person on ART has higher-than-normal lactic acid levels to begin with, it might not be wise for such a person to further exacerbate things by adding Metformin.

Between rosiglitazone and pioglitazone, pioglitazone seems to be a better choice for people with lipodystrophy, because it has a better lipid profile. According to this report, rosi increases LDL and triglycerides, while pio decreases LDL and trigs.
http://www.diabetesincontrol.com/issue134/item11.shtml
http://www.diabetesincontrol.com/issue134/item11.shtml

Glenn


#2155 From: GetWell@...
Date: Thu Feb 27, 2003 10:28 pm
Subject: Re: [lipodystrophy] Off Topic: Anal Pap smears urged for gay men
getwell5
Offline Offline
Send Email Send Email
 
Thanks for this good information. While the proper course of treatment for
low-grade lesions might be questionable, no one should ever use that as an
excuse to avoid follow-up examinations. It needs to be monitored! This would
include anyone who has ever had surgery for anal warts.

There is an anal clinic in Boston where they specialize in this. They are
currently seeing me every year. Each visit includes an anal pap smear and an
anal colposcopy which is recorded on videotape and kept as a reference to
compare with future examinations.

Here is a website for the clinic:
http://home.caregroup.org/templatesnew/links/cat_out.asp?pageid=4042

Here is a brief Q & A from one of the doctors at the clinic:
http://www.neaetc.org/qa/Answers/qa_answer_4.20.01.htm

I apologize for my continuation of this subject and will now try to stick with
"Lipodystrophy", which I am mostly interested in.

Glenn


In a message dated 2/27/2003 3:01:19 PM Eastern Standard Time, ROLYATFFEJ
writes:

> Yes, HPV is a huge problem for all gay men--especially those of us with HIV
> in whom it can progress much more quickly into cancer.  Doctors with large
> gay and HIV+ patient loads have known for years that they can do an anal pap
> smear, and that if they do, they're likely to find pre-cancerous lesions.
> The question is: what do you do about them?  There is no established standard
> of care for treating lesions, especially low grade ones, once they've been
> detected.  Many low grade lesions spontaneously go away without ever
> progressing, and even high grade ones often just sit there for years without
> progressing or causing problems.  So the dilemma for physicians is whether to
> aggressively treat them topically with Aldara or 5FU, burn them off with
> acids like BCA or podophyllin, or employ more drastic slash-and-burn
> techniques like surgery using electro-cautery, excision, or laser.  These
> treatments range from messy and uncomfortable to excruciatingly painful and
> debilitating with long recovery periods.  So naturally physicians are
> unwilling to subject patients to these treatments without some assurance of
> their necessity and efficacy.
>
> The AIDS Malignancy Consortium, to which I am a new community representative,
> is the NIH group that splintered off from the ACTG and is funded research
> AIDS-associated cancers, including HPV.  They are too small to do the large
> cohort studies needed to determine rates of occurrence and disease
> progression.  Currently they are doing small pilot studies of promising
> treatments, including a vaccine study spearheaded by Joel Palefsky--arguably
> the leading expert on HPV disease in men.  What is needed, IMHO, is
> collaboration with larger NIH funded research groups like the ACTG or CPCRA
> to determine rates of incidence & disease progression, and to screen the
> large numbers of patients needed to obtain subjects for treatment trials.
>
> In the meantime, it's up to us as patients to insist that our primary care
> physicians and proctologists (finding an HIV-savvy proctologist is the
> biggest problem for many of us--I had to drive 120 mi to LA to find one) and
> insisting that they look for the problem in the first place--using pap smears
> or acetic acid staining.  Once found, we need to work with them on treating
> them using the currently available options.  Many proctologists wait until
> there is a frank visible lesion or wart to remove before using the removal
> technique they're trained to do (and just as importantly--get reimbursed
> for.)
>
> Networking with each other about savvy treating physicians and treatments
> that work is key, given the dearth of received knowledge on the subject.  To
> share my experience, I burned through three different so-called specialists
> who diagnosed my in situ squamous cell carcinoma, but failed to treat
> it--preferring to "wait and see."  I finally located a proctologist who used
> laser, which is less traumatic and heals faster, who not only removed the
> cancerous lesion, but at the same time used laser ablation to resurface the
> entire perianal area to eliminate any other possible pre-cancerous growths.
> This drastically reduced the rate of recurrences.  On my regular checkups, if
> anything new is detected, he typically applies podophyllin not only to the
> lesion or condyloma, but again to the entire perianal area to ablate away any
> low grade cells that may be lurking.  This seems to work for me, but like
> many HIV+ men  I'm stuck with a lifetime of having to have regular checkups
> and removal.
>
> I realize this raises a lot more questions than it answers, but I hope it
> helps.  In addition to treatment advocacy, I think we should lobby the newly
> formed Academy of HIV Medicine and the GLMA to include anal HPV lesion
> monitoring as standard of care for all sexually active gay men--especially
> those who are HIV+.  If there are any list members who work
> with either of
> these groups, perhaps they could help us advocate for this.
>
> Jeff Taylor

#2154 From: PoWeRTX@...
Date: Thu Feb 27, 2003 3:35 pm
Subject: Re: [lipodystrophy] Should we stop off topic emails?
PoWeRTX@...
Send Email Send Email
 
In a message dated 2/27/03 12:44:52 PM Central Standard Time, mal@... writes:

Most of these stories: e.g.. Pap smears, etc. are featured at the AEGIS news service which can be delivered to a subscriber on a daily basis.  And POZ members usually discuss all this stuff anyway when they are not off on some completely unrelated tangent. 
On a positive note, I did find a lot of those members were well informed and very helpful.
 
Anyway, I've made my point and hope I did not offend anyone.


Thank you. You have a point. As the moderator, I may have to think very carefully about your suggestion. I may just decide to stop (my own and others) off topic emails.

If you could, can you email me a list of other email lists that you are subscribed to that are pertinent to other issues?. I would like to provide that list to the 280 members of this list that may not be aware of them so that we do not have to go off topic so much. Thanks!

Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health


#2153 From: rolyatffej@...
Date: Thu Feb 27, 2003 3:01 pm
Subject: Re: [lipodystrophy] Off Topic: Anal Pap smears urged for gay men
rolyatffej
Offline Offline
Send Email Send Email
 
Nelson et al--

Yes, HPV is a huge problem for all gay men--especially those of us with HIV
in whom it can progress much more quickly into cancer.  Doctors with large
gay and HIV+ patient loads have known for years that they can do an anal pap
smear, and that if they do, they're likely to find pre-cancerous lesions.
The question is: what do you do about them?  There is no established standard
of care for treating lesions, especially low grade ones, once they've been
detected.  Many low grade lesions spontaneously go away without ever
progressing, and even high grade ones often just sit there for years without
progressing or causing problems.  So the dilemma for physicians is whether to
aggressively treat them topically with Aldara or 5FU, burn them off with
acids like BCA or podophyllin, or employ more drastic slash-and-burn
techniques like surgery using electro-cautery, excision, or laser.  These
treatments range from messy and uncomfortable to excruciatingly painful and
debilitating with long recovery periods.  So naturally physicians are
unwilling to subject patients to these treatments without some assurance of
their necessity and efficacy.

The AIDS Malignancy Consortium, to which I am a new community representative,
is the NIH group that splintered off from the ACTG and is funded research
AIDS-associated cancers, including HPV.  They are too small to do the large
cohort studies needed to determine rates of occurrence and disease
progression.  Currently they are doing small pilot studies of promising
treatments, including a vaccine study spearheaded by Joel Palefsky--arguably
the leading expert on HPV disease in men.  What is needed, IMHO, is
collaboration with larger NIH funded research groups like the ACTG or CPCRA
to determine rates of incidence & disease progression, and to screen the
large numbers of patients needed to obtain subjects for treatment trials.

In the meantime, it's up to us as patients to insist that our primary care
physicians and proctologists (finding an HIV-savvy proctologist is the
biggest problem for many of us--I had to drive 120 mi to LA to find one) and
insisting that they look for the problem in the first place--using pap smears
or acetic acid staining.  Once found, we need to work with them on treating
them using the currently available options.  Many proctologists wait until
there is a frank visible lesion or wart to remove before using the removal
technique they're trained to do (and just as importantly--get reimbursed
for.)

Networking with each other about savvy treating physicians and treatments
that work is key, given the dearth of received knowledge on the subject.  To
share my experience, I burned through three different so-called specialists
who diagnosed my in situ squamous cell carcinoma, but failed to treat
it--preferring to "wait and see."  I finally located a proctologist who used
laser, which is less traumatic and heals faster, who not only removed the
cancerous lesion, but at the same time used laser ablation to resurface the
entire perianal area to eliminate any other possible pre-cancerous growths.
This drastically reduced the rate of recurrences.  On my regular checkups, if
anything new is detected, he typically applies podophyllin not only to the
lesion or condyloma, but again to the entire perianal area to ablate away any
low grade cells that may be lurking.  This seems to work for me, but like
many HIV+ men  I'm stuck with a lifetime of having to have regular checkups
and removal.

I realize this raises a lot more questions than it answers, but I hope it
helps.  In addition to treatment advocacy, I think we should lobby the newly
formed Academy of HIV Medicine and the GLMA to include anal HPV lesion
monitoring as standard of care for all sexually active gay men--especially
those who are HIV+.  If there are any list members who work with either of
these groups, perhaps they could help us advocate for this.

Jeff Taylor

#2152 From: MAL <mal@...>
Date: Fri Feb 28, 2003 6:51 am
Subject: Re: [lipodystrophy] Off Topic: Anal Pap smears urged for gay men
topcut33
Offline Offline
Send Email Send Email
 
Just a comment about this site. 
 
There is a lot of information being disseminated about HIV related conditions other than lipodystrophy.
 
I subscribed to this site because of lipodystrophy and would hope that if this site remains on the topic.
 
I subscribed to the POZ forum before and eventually unsubscribed because of 'off the topic' issues.
 
It became a venting ground for bitter unhappy gay men with aids discussing everything from religion to politics.
Completely unrelated to AIDS and AIDS conditions.
 
Most of these stories: e.g.. Pap smears, etc. are featured at the AEGIS news service which can be delivered to a subscriber on a daily basis.  And POZ members usually discuss all this stuff anyway when they are not off on some completely unrelated tangent. 
On a positive note, I did find a lot of those members were well informed and very helpful.
 
Anyway, I've made my point and hope I did not offend anyone.
 
 
 
 
----- Original Message -----
Sent: Thursday, February 27, 2003 8:57 AM
Subject: Re: [lipodystrophy] Off Topic: Anal Pap smears urged for gay men

In a message dated 2/27/03 7:02:02 AM Central Standard Time, GetWell@... writes:

Yahoo! News - Anal Pap smears urged for gay men
http://story.news.yahoo.com/news?tmpl=story2&u=/po/20030226/co_po/anal_pap_s
mears_urged_for_gay_men


I had one done by Dr Ford Kinder in Miami. He went to a two day seminar on this topic. The main problem is that more than 60 % of the time the results come back inconclusive. And most of us are poz to HPV, which makes us have a much greater risk of anal cancer. Jeff Taylor is sitting in a NHI committee that deals with research in this area (Jeff, are you there? could you add anything else for us?)

Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health



To unsubscribe from this group, send an email to:
lipodystrophy-unsubscribe@yahoogroups.com

If you received this email from someone who forwarded it to you and would like to join this group, send a blank email to lipodystrophy-subscribe@yahoogroups.com and you will get an email with intructions to follow. You can chose to receive single emails or a daily digest (collection of emails). You can post pictures, images, attach files and search by keyword old postings in the group.

For those of you who are members already and want to switch from single emails to digest or viceversa, visit www.yahoogroups.com, click on lipodystrophy, then on "edit my membership" and go down to your selection. The list administrator does not process any requests, so this is a do-it-yourself easy process ! :)
Thanks for joining. You will learn and share a lot in this group!

Forward this email to anyone who may benefit from this information! Thanks!
In Health,

Nelson Vergel
Interim List Administrator


Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.

#2151 From: PoWeRTX@...
Date: Thu Feb 27, 2003 1:16 pm
Subject: Re: [lipodystrophy] Re: Oxandrin and Lipo
PoWeRTX@...
Send Email Send Email
 
In a message dated 2/27/03 12:07:55 PM Central Standard Time, mmooney@... writes:

The best combo to decrease fat, visceral or other (subcutaneous) fat is GH, an oral steroid like Oxandrin, Winstrol (which costs less) or Anadrol, and Metformin (MET, if there is no chance of lactic acidosis). There should be a base of testosterone, and perhaps nandrolone for anabolic effect, but they too can decrease subcutaneous fat. Take glutamine too, as it helps improve insulin sensitivity. Glutamine appears to enhance fat loss in two studies of rats, and in my personal experience.
 
Michael Mooney


I would rather see more work on Avandia (rosiglitazone) and Actos (pioglitazone) than Glucophage (Metformin). Metformin seems to be anorexic (causes weight loss), cause hypoglycemia, cause diarrhea, and may cause lactic acidosis (which we have not seen in studies yet) whereas Avandia and Actos do not. These insulin sensitizers may also help keep glucose down when using Serostim (Serostim may worsen insulin resistance). I am also very concerned about the use of oral anabolic steroids by those with pre-existing liver disease, Hep C and high liver enzymes.

Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health


#2150 From: rickrackb@...
Date: Thu Feb 27, 2003 1:08 pm
Subject: Re: [lipodystrophy] Off Topic: Anal Pap smears urged for gay men
rickrackb
Offline Offline
Send Email Send Email
 
I had one done in Atlanta by a very enlightened straight doctor.  He did comment that unless it is sent to a lab that knows how to handle an anal pap smear, it will be completely useless.  So if "that lab" is not included in your insurance plan, it would probably be worth the extra money out of your pocket for it to be sent there.

Rick

========Original Message========
Subj: Re: [lipodystrophy] Off Topic: Anal Pap smears urged for gay men
Date: 2/27/2003 11:59:56 AM Eastern Standard Time
From: PoWeRTX@...
To: GetWell@...
CC: lipodystrophy@yahoogroups.com, ROLYATFFEJ@...
Sent from the Internet (Details)



In a message dated 2/27/03 7:02:02 AM Central Standard Time, GetWell@... writes:

Yahoo! News - Anal Pap smears urged for gay men
http://story.news.yahoo.com/news?tmpl=story2&u=/po/20030226/co_po/anal_pap_s
mears_urged_for_gay_men


I had one done by Dr Ford Kinder in Miami. He went to a two day seminar on this topic. The main problem is that more than 60 % of the time the results come back inconclusive. And most of us are poz to HPV, which makes us have a much greater risk of anal cancer. Jeff Taylor is sitting in a NHI committee that deals with research in this area (Jeff, are you there? could you add anything else for us?)

Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health


Yahoo! Groups Sponsor
ADVERTISEMENT




To unsubscribe from this group, send an email to:
lipodystrophy-unsubscribe@yahoogroups.com

If you received this email from someone who forwarded it to you and would like to join this group, send a blank email to lipodystrophy-subscribe@yahoogroups.com and you will get an email with intructions to follow. You can chose to receive single emails or a daily digest (collection of emails). You can post pictures, images, attach files and search by keyword old postings in the group.

For those of you who are members already and want to switch from single emails to digest or viceversa, visit www.yahoogroups.com, click on lipodystrophy, then on "edit my membership" and go down to your selection. The list administrator does not process any requests, so this is a do-it-yourself easy process ! :)
Thanks for joining. You will learn and share a lot in this group!

Forward this email to anyone who may benefit from this information! Thanks!
In Health,

Nelson Vergel
Interim List Administrator

Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.

#2149 From: Michael Mooney <mmooney@...>
Date: Thu Feb 27, 2003 6:04 pm
Subject: Re: Oxandrin and Lipo
michaelmoone...
Offline Offline
Send Email Send Email
 
> > Lars here, from Sydney.
> > I am considering going on Oxandrin to combat lipo... I have "road
> > map veins" on my legs. I think my abs are being pushed out from the
> > inside, by visceral, not subcutaneous fat.
> > I have been told that maintenance dose of Oxandrin can keep the lipo
> > at bay. Who uses it and how much?
> > Thanks!
> > L in S 

>
> L : I am assuming you are a man. There are no data on Oxandrin and
> lipodystrophy. I only saw one abstract in a conference somewhere (I can not
> pull it out of Medline somehow) that showed that a doctor in Dallas used it
> on lipo patients and they lost visceral fat. You need at least 20 mg/day with
> background 200 mg/ every two week testosterone replacement. It may increase
> your subcutaneous fat loss and increase your liver enzymes. You may want to
> read about nandrolone (deca durabolin) in www.medibolics.com as a better
> option.
>
In a J of Obesity study nandrolone did not decrease visceral fat while Oxandrin did. (In fact nandrolone slightly increased it.) Oral steroids like Oxandrin do this by increasing post-heparin hepatic triglyceride lipase (breaks down fat), which injectables DO NOT do. Any of the orals has a better chance of decreasing visceral (and other) fat than injectables. Winstrol, and Anadrol do it too.

I have the same issue with abs being pushed out by visceral fat. There's nothing to pinch because it is all under the muscle layer. When it gets real bad you might even see what has been referred to as the "alien baby" when you do sit-ups or crunches. The technical term for the "alien baby" is diastasis recti. As far as anabolics are concerned, I'm 100% in agreement with Nelson, that nandrolone is a better option than Oxandrin. I also know that nandrolone IS available in Australia and does get prescribed to HIV patients. As Nelson suggested, check out the Medibolics website.

Having said that, I also should add that my understanding is that anabolics (including nandrolone) are NOT the best option for reducing truncal obesity. Growth Hormone is more effective, as well as some diabetes drugs (Metformin, Pioglitazone, Rosiglitazone). Of course, much depends on your individual case. While anabolics may not cure truncal obesity, they are still BEST for building muscle, and more muscle mass in your chest and arms can help lessen the embarrassing appearance of the lipo belly. 

The best combo to decrease fat, visceral or other (subcutaneous) fat is GH, an oral steroid like Oxandrin, Winstrol (which costs less) or Anadrol, and Metformin (MET, if there is no chance of lactic acidosis). There should be a base of testosterone, and perhaps nandrolone for anabolic effect, but they too can decrease subcutaneous fat. Take glutamine too, as it helps improve insulin sensitivity. Glutamine appears to enhance fat loss in two studies of rats, and in my personal experience.
 
Michael Mooney
www.michaelmooney.net --- soon to be uploaded
 

#2148 From: PoWeRTX@...
Date: Thu Feb 27, 2003 11:57 am
Subject: Re: [lipodystrophy] Off Topic: Anal Pap smears urged for gay men
PoWeRTX@...
Send Email Send Email
 
In a message dated 2/27/03 7:02:02 AM Central Standard Time, GetWell@... writes:

Yahoo! News - Anal Pap smears urged for gay men
http://story.news.yahoo.com/news?tmpl=story2&u=/po/20030226/co_po/anal_pap_s
mears_urged_for_gay_men


I had one done by Dr Ford Kinder in Miami. He went to a two day seminar on this topic. The main problem is that more than 60 % of the time the results come back inconclusive. And most of us are poz to HPV, which makes us have a much greater risk of anal cancer. Jeff Taylor is sitting in a NHI committee that deals with research in this area (Jeff, are you there? could you add anything else for us?)

Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health


#2147 From: "getwell5 <GetWell@...>" <GetWell@...>
Date: Thu Feb 27, 2003 2:58 pm
Subject: Re: High blood pressure treatment
getwell5
Offline Offline
Send Email Send Email
 
--- In lipodystrophy@yahoogroups.com, "doug.neville"
<doug.neville@a...> wrote:
> After having high blood pressure (140/106) for several months, I
finally agreed to taking medication to help.  My doc prescribed
Maxzide and within 3 days I was feeling punch drunk and stupid.  He's
switched me off of that to Hydrochlorothiazide instead.  My
question:  I recently read about blood pressure lowering effects of
Avandia, but my doc dismissed it, saying that the numbers and
impressions coming out of Boston don't support it.
>
> What are you guys/gals doing about high blood pressure?  Are there
alternatives to Hydrochlorothiazide?

Hydrochlorothiazide is pretty harmless. I wouldn't worry too much
about it. It may end up not being enough by itself though.  In my
case, I take Moexipril (Univasc) which is an ACE inhibitor, as well
as Hydrochlorothiazide.

More importantly though, before you try all these drugs, have you had
any tests done to determine if there is some root cause for your
hypertension?  24-Hour urine tests are pretty common as a preliminary
test.

Glenn

#2146 From: GetWell@...
Date: Thu Feb 27, 2003 8:53 am
Subject: Easing Lipodystrophy in Women
getwell5
Offline Offline
Send Email Send Email
 
<><><><><><><><><><><><><><><><><><><><>
Easing Lipodystrophy in Women
<><><><><><><><><><><><><><><><><><><><>

Doctors still aren't sure how lipodystrophy can be treated, but there
are some steps women can take to lessen the symptoms. ACRIA's
"Treatment Issues for Women" guide provides some tips.
   http://www.thebody.com/cria/women/treatment_issues_women_5.html
   AOL users: click here



#2145 From: GetWell@...
Date: Thu Feb 27, 2003 8:43 am
Subject: Re: Oxandrin and Lipo
getwell5
Offline Offline
Send Email Send Email
 
--- In lipodystrophy@yahoogroups.com, PoWeRTX@... wrote:
> In a message dated 2/26/03 4:42:55 PM Central Standard Time,
> (lars3@... writes:
>
> > Lars here, from Sydney.
> > I am considering going on Oxandrin to combat lipo... I have "road
> > map veins" on my legs. I think my abs are being pushed out from the
> > inside, by visceral, not subcutaneous fat.
> > I have been told that maintenance dose of Oxandrin can keep the lipo
> > at bay. Who uses it and how much?
> > Thanks!
> > L in S
> >
>
> L : I am assuming you are a man. There are no data on Oxandrin and
> lipodystrophy. I only saw one abstract in a conference somewhere (I can not
> pull it out of Medline somehow) that showed that a doctor in Dallas used it
> on lipo patients and they lost visceral fat. You need at least 20 mg/day with
> background 200 mg/ every two week testosterone replacement. It may increase
> your subcutaneous fat loss and increase your liver enzymes. You may want to
> read about nandrolone (deca durabolin) in www.medibolics.com as a better
> option.
>
> Nelson Vergel

I have the same issue with abs being pushed out by visceral fat. There's nothing to pinch because it is all under the muscle layer. When it gets real bad you might even see what has been referred to as the "alien baby" when you do sit-ups or crunches. The technical term for the "alien baby" is diastasis recti. As far as anabolics are concerned, I'm 100% in agreement with Nelson, that nandrolone is a better option than Oxandrin. I also know that nandrolone IS available in Australia and does get prescribed to HIV patients. As Nelson suggested, check out the Medibolics website.

Having said that, I also should add that my understanding is that anabolics (including nandrolone) are NOT the best option for reducing truncal obesity. Growth Hormone is more effective, as well as some diabetes drugs (Metformin, Pioglitazone, Rosiglitazone). Of course, much depends on your individual case. While anabolics may not cure truncal obesity, they are still BEST for building muscle, and more muscle mass in your chest and arms can help lessen the embarrassing appearance of the lipo belly.

Glenn


#2144 From: GetWell@...
Date: Thu Feb 27, 2003 8:00 am
Subject: Off Topic: Anal Pap smears urged for gay men
getwell5
Offline Offline
Send Email Send Email
 
Yahoo! News - Anal Pap smears urged for gay men
http://story.news.yahoo.com/news?tmpl=story2&u=/po/20030226/co_po/anal_pap_s
mears_urged_for_gay_men

Anal Pap smears urged for gay men
Tue Feb 25, 7:54 PM ET

Gay.com U.K.


SUMMARY: Doctors are urging gay men who regularly have anal intercourse to undergo regular Pap smear testing, after new studies show they may be more than 30 times more likely to suffer from anal cancer.

Doctors are urging gay men who regularly have anal intercourse to undergo regular Pap smear testing, after new studies show they may be more than 30 times more likely to suffer from anal cancer.

Researchers from the Harvard School of Public Health say that men with HIV (news - web sites) are even more at risk.

An anal Pap smear, which involves taking tissue samples from the wall of the rectum, is a similar procedure to the cervical smear tests used to detect cancer of the cervix in women.

Both cervical and anal cancers are linked to infection with certain varieties of the human papillomavirus, or HPV, and can prove fatal if not detected early enough.

A 1998 study published in the Journal of Infectious Diseases showed that 61 percent of HIV-negative gay men in San Francisco, and 93 percent of HIV-positive gay men, were infected with some form of HPV.

_________________________________________

If you'd like to know more, you can find stories related to Anal Pap smears urged for gay men.




#2143 From: PoWeRTX@...
Date: Wed Feb 26, 2003 6:01 pm
Subject: Oxandrin and Lipo
PoWeRTX@...
Send Email Send Email
 
In a message dated 2/26/03 4:42:55 PM Central Standard Time, lars3@... writes:

Lars here, from Sydney.
I am considering going on Oxandrin to combat lipo... I have "road
map veins" on my legs. I think my abs are being pushed out from the
inside, by visceral, not subcutaneous fat.
I have been told that maintenance dose of Oxandrin can keep the lipo
at bay. Who uses it and how much?
Thanks!
L in S


L : I am assuming you are a man. There are no data on Oxandrin and lipodystrophy. I only saw one abstract in a conference somewhere (I can not pull it out of Medline somehow) that showed that a doctor in Dallas used it on lipo patients and they lost visceral fat. You need at least 20 mg/day with background 200 mg/ every two week testosterone replacement. It may increase your subcutaneous fat loss and increase your liver enzymes. You may want to read about nandrolone (deca durabolin) in www.medibolics.com as a better option.


Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health


#2142 From: "larsk3 <lars3@...>" <lars3@...>
Date: Wed Feb 26, 2003 10:39 pm
Subject: Who uses Oxandrin and how much for lipo...
larsk3
Offline Offline
Send Email Send Email
 
Lars here, from Sydney.
I am considering going on Oxandrin to combat lipo... I have "road
map veins" on my legs. I think my abs are being pushed out from the
inside, by visceral, not subcutaneous fat.
I have been told that maintenance dose of Oxandrin can keep the lipo
at bay. Who uses it and how much?
Thanks!
L in S

#2141 From: pozbod <pozbod@...>
Date: Wed Feb 26, 2003 5:38 pm
Subject: Blood pressure and Avandia
johnftl59
Offline Offline
Send Email Send Email
 
On Wednesday, Feb 26, 2003, at 10:41 US/Eastern,
lipodystrophy@yahoogroups.com wrote:

>  My question:  I recently read about blood pressure lowering effects
> of Avandia, but my doc dismissed it, saying that the numbers and
> impressions coming out of Boston don't support it.
>

The use of Avandia for insulin insensitivity/lipo problems in HIV is
early in development, and while promising, there are no definitive
answers, and more than a few negative reports.  Your BP is high, and
treating with HCTZ is generally safe, effective, and cheap.

JB

#2140 From: pozbod <pozbod@...>
Date: Wed Feb 26, 2003 5:34 pm
Subject: Tiredness on workouts
johnftl59
Offline Offline
Send Email Send Email
 
On Wednesday, Feb 26, 2003, at 10:41 US/Eastern,
lipodystrophy@yahoogroups.com wrote:

>  It's also the dead of winter in
> Chicago and that could be contributing to it, but then again maybe not.
> I've been reading about mitochondrial toxicity and the effects it has
> on
> energy production, but also read that the drugs I'm taking aren't major
> offenders.
>

Carl,
There are so many reasons for the constellations of things you describe
that I would not rush to the drugs as the reason.  I would, though,
discuss this at length with your doctor.  He/she needs to be aware of
the problem so that you can begin to find a solution.

JB

#2139 From: Joey <joeyc@...>
Date: Wed Feb 26, 2003 4:00 pm
Subject: Exercise History
joeyc@...
Send Email Send Email
 
Just for anecdotal purposes, could anyone tell me if they
were regular exercisers before starting HAART? And if you remained
an exerciser since, how you view the intensity of your lipodystrophy.
Feel free to email directly.
Thanks
Joey

#2138 From: PoWeRTX@...
Date: Wed Feb 26, 2003 1:39 am
Subject: dverse Drug Reactions, Metabolic Complications and Lipodystrophy: Selected Highl
PoWeRTX@...
Send Email Send Email
 
Adverse Drug Reactions, Metabolic Complications and Lipodystrophy: Selected Highlights from the 10th CROI By Andrew Carr, MD
Dr. Carr is Staff Specialist in Immunology/HIV Medicine at St. Vincent's Hospital in Sydney, Australia and Associate Professor of Medicine at the University of New South Wales, Sydney, Australia. He is also a Contributing Editor to HIVandHepatitis.com
• Lipodystrophy • Cardiovascular Disease
• Dyslipidaemia • Bone Disease
• Insulin Resistance • Neurotoxicity
• Mitochondrial Toxicity


Lipodystrophy
Buffalo HumpFollowing on from the somewhat controversial presentation of the FRAM study at Barcelona, the study had 3 adjacent posters, one of which presented new data (abstracts 732-734). At Barcelona, we were told that buffalo hump was as common in men with and without HIV infection. Further analysis of these data found that buffalo hump was significantly associated with greater total, arm, head and intra-abdominal fat than in those without buffalo hump. Furthermore, buffalo humps in men with HIV infection were larger (8 x 8 cm) than in men without HIV infection (5 x 4.5 cm). No analysis was presented as to the impact of antiretroviral therapy, HIV disease parameters or patient characteristics on the prevalence or size of buffalo hump. Whether the fat accumulation observed in the 2 populations are the same or pathogenetically different or similar cannot be determined, of course, without pathological investigations.

Lipoatrophy and Fat Accumulation in the Women's Interagency HIV Study
An interesting presentation reported on the prevalence of lipoatrophy and fat accumulation in the Women's Interagency HIV Study (abstract 736). As was shown cross-sectionally in FRAM, HIV-infected women had more frequent onset of peripheral lipoatrophy than did HIV-uninfected women (30% and 12%, respectively). The same applied for central lipoatrophy (25% and 15%). It is not clear that this atrophy is ART-induced, HIV wasting, both or neither. Nevertheless, the incidence of fat accumulation was similar both centrally and peripherally in both groups, suggesting that at least some of the fat accumulation reported as HIV lipodystrophy-related is age-related (or at the very least not all is HIV/ART-related). The question remains how much.

Lipodystrophy Case Definition

Ongoing analysis of the HIV lipodystrophy case definition study (abstract 731) data found that subjective clinical lipodystrophy severity (both physician and patient assessed) correlated significantly with 6 objective measures of lipodystrophy severity. These 6 measures included trunk:limb fat ratio on DEXA, VAT:SAT ratio on abdominal CT scan, and waist:hip ratio using a tape measure. However, the best correlate was the lipodystrophy case definition score, being the score used to diagnose lipodystrophy that is derived from the 10 objective parameters in the lipodystrophy case definition (age, gender, HIV duration, CDC stage, waist:hip ratio, anion gap, HDL cholesterol, trunk:limb fat ratio, VAT:SAT and leg fat percent). Furthermore, the case definition score correlated well with multiple lipid, glycaemic and acid-base parameters that we know correlate with lipodystrophy severity; this correlation was better than that using subjective lipodystrophy severity scores. These data suggest that this case definition can used to objectively both diagnose and rate the severity of lipodystrophy. This score has the added advantage, unlike DEXA and CT, of generating gender-independent values, meaning that a single scoring system could be used to develop a grading scale for use in clinical trials. Of course, this possibility needs prospective validation. Dual NRTI Switch to EfavirenzA non-randomised switch study from dual NRTI therapy to efavirenz plus boosted indinavir found that peripheral fat increased, but that visceral fat increased also (abstract 738). It was inferred that nucleosides play a greater role in lipoatrophy than does boosted indinavir (but what about other protease inhibitors?). The authors also suggested that the mechanisms leading to visceral fat gain might be separate, at least in part, to those responsible for peripheral fat loss, and that maybe protease inhibitors really do specifically lead to increases in central fat independently of changes in peripheral fat.

Dyslipidaemia
2NN StudyLipid changes in the 2NN study comparing efavirenz, nevirapine or both with a background of d4T/3TC (abstract 752). There were significant changes with both EFV and NVP, although the lipid changes were slightly more favourable with NVP, particularly for triglycerides and total:HDL cholesterol ratio (the best lipid predictor of cardiovascular disease). Unfortunately, glycaemic data were not presented.
Niacin Pilot StudyA pilot study evaluated the value of niacin in 14 HIV-infected adults with LDL cholesterol at least 130 mg/dl and triglycerides at least 200 mg/dl (abstract 726). Patients initiated the NCEP step 1 diet for 4 weeks, then added niacin (500 mg daily, increasing by 500 mg every 2 weeks if tolerated to a maximum of 2000 mg daily) for 14 weeks. 6 patients experienced flushing, and 2 ceased niacin for this reason. In terms of efficacy, total cholesterol and triglycerides both declined significantly (14% and 34%, respectively). However, LDL cholesterol did not alter, and there was evidence that insulin resistance worsened. So this intervention cannot be recommended without further evaluation.

Insulin Resistance Two groups found that the adipocyte cytokine, adiponectin, was a better marker of insulin sensitivity than the other major adipokine, leptin (abstracts 754 and 757). Adiponectin levels also correlated with lipodystrophy severity on imaging. Whether measurement of adiponectin is useful for diagnosing either abnormal glucose tolerance or lipodystrophy cannot be determined from these cross-sectional data, although they do suggest a role for adiponectin in the pathogenesis of both.

Mitochondrial Toxicity

MtDNA as Marker of NRTI-related LipoatrophySeveral groups reported on the utility of measuring mitochondrial DNA (mtDNA) in either peripheral blood mononuclear cells or subcutaneous fat as a marker of nucleoside analog-related lipoatrophy (abstracts 133, 728, 729, 739). Overall, significant differences in mtDNA levels were much more likely to be observed when subcutaneous fat was used, with lower levels in those with peripheral neuropathy and/or subjective lipoatrophy. The variability of change was not well reported, however, nor was a comparison of the technique with DEXA, which directly measures peripheral, subcutaneous fat mass. Also, the variability cross-sectionally was quite substantial when ART-naïve and ART-exposed subjects were compared, suggesting the test may not be that useful diagnostically. Of course, not all lipoatrophy involves nucleoside analog mitochondrial toxicity, and so it is not surprising that an assay that only assesses the lipotoxicity of one drug class would have limited value.

Rare Renal Tubular Illness with TenofovirTwo posters (numbers 717 and 718) reported on a total of 6 patients who developed a Fanconi-like renal tubular illness while receiving tenofovir therapy. This illness comprised hypophosphataemia, elevated serum creatinine, myalgias and fatigue, and is similar to that frequently observed with adefovir therapy at high doses (at least 60 mg daily). Indeed, 3 of the 6 patients had developed this illness previously on adefovir. On this occasion, and in contrast to adefovir, in some patients the illness did not recur when tenofovir was recommenced with phosphate supplementation. Overall, the condition does appear to be rare and less severe than with adefovir, but perhaps it is worth measuring phosphate and creatinine levels in patients receiving tenofovir. With such small numbers of cases, we still do not know who might be at risk of this toxicity with tenofovir therapy

.

Cardiovascular DiseaseIt remains controversial whether exposure to combination antiretroviral treatment (ART) leads to an accelerated risk of myocardial infarction (MI), possibly via dyslipidaemia and insulin resistance, perhaps by altering the inflammatory milieu, or perhaps by promoting thrombosis. Several studies reported data with conflicting results.

D:A:D Prospective Observational StudyProbably the most important single presentation of new toxicity data at the conference was the D:A:D study (abstract 130). D:A:D is an ongoing prospective observational study of 23,468 patients from 11 cohorts in Europe, USA and Australia, enrolled from July 1999 to April 2001 with follow-up analysed through February 2002. Assess the incidence of MI in a population of HIV infected individuals. The studies objectives were:

1.       to assess the association of exposure to combination ART with incidence of MI; and 2.       to identify factors associated with increased risk of MI
The study was powered to detect a 2-fold increase in the rate of MI in patients receiving 3-drug antiretroviral therapy (in 99% of patients 1-2 nucleosides plus either a protease inhibitor and/or a non-nucleoside reverse transcriptase inhibitor) relative to those who were ART-naive. Follow-up FU was to Feb 1st 2002, last visit to an HIV clinic + 6 months, the date of 1st MI or date of death, whichever occurred first.
23,468 patients were followed for a total of 36,199 patient years after enrolment. Their median age was 39 years, 24% were female, 45% had acquired HIV through homosexual sex, and 20% by injecting drug use, 26% had a prior clinical AIDS diagnosis, the median Cd4 count was 418, and 55% of subjects had an undetectable plasma HIV RNA. In terms of antiretroviral exposure, 67% had received a PI (median 2.6 years), 34% a nonnucleoside analog reverse transcriptase inhibitor (median 0.9 years) and 81% a nucleoside analog RTI (median 3.3 years), leaving 19% antiretroviral-naïve (the patients has been enrolled in their local cohorts well before enrollment into D:A:D so their total ART exposure was greater).Using WHO definitions of definite, probable and unclassifiable acute myocardial infarctions (based upon presence of cardiac pain, cardiac enzymes, troponin, EKG changes, and autopsy findings) 126 patients developed a 1st MI. The overall incidence of acute MI was 3.5 per 1000 person years (PY). Of these, 28% were fatal (survival less than 28 days). These deaths represented 7% of all deaths on study, with by far the greater being HIV-related, even in the presence of so much ART. Using WHO criteria, 55% were definitive, 29% possible, and 16% unclassifiable.The incidence of MI increased with longer exposure to CART (RR per year of exposure was 1.26 [95% confidence interval 1.12-1.41, p<0.0001]) after adjustment for demographic risk factors, including increasing age with increased time on CART. Quite amazingly, the increase in risk became apparent after only 1 year's therapy with combination ART, and appeared linear out to 4 years of therapy (too few patients have been followed for longer than 4 years to produce reliable estimates). Other factors associated with MI were: age (per 5 years increase: RR 1.38), current or ex-smoking status (RR 2.17), history of cardiovascular disease (RR 5.84) and male gender (RR 1.99), but not family history of cardiovascular disease. Total serum cholesterol level and diabetes mellitus were also associated with an increased rate, but (possibly) not independently of each other. The relationship between increased exposure to CART and the rate of MI tended to be reduced after adjustment for total cholesterol, but was unaffected by adjustment for nadir and current CD4+ lymphocyte count, level of HIV-RNA, duration of HIV infection, and presence of diabetes or lipodystrophy. Interestingly, the presence of clinically detected lipodystrophy (lipoatrophy or abnormal fat gain) tended to be associated with a reduced risk of MI on simple univariate analysis and after adjustment for body mass index and cholesterol. No one could explain this finding. The authors also noted that the absolute risk of MI appeared low and should be balanced with the marked benefit of antiretroviral treatment. They presented no data as to whether any particular subgroup was at higher baseline risk of MI, by virtue of ART exposure, than at risk of AIDS without ART exposure. One of the first questions that arose was the relative contributions of each antiretroviral drug class, and of individual drugs, to the increased risk observed. The authors stated that these analyses had not occurred yet as too few patients had developed and MI to allow for such subanalyses. However, follow-up of D:A:D will continue until at least 2005, and so another 100-200 definite or probable MIs should occur and so increase the power of the study to allow such analyses. It was also noted that HDL cholesterol did not figure in the presentation; this was because HDL cholesterol data was missing for about the study participants (it was not collected routinely in some cohorts). So why has D:A:D yielded significantly different results to other observational cohort studies, in particular the VA study presented by Sam Bozzette last year at this meeting? There are numerous significant differences between these studies that appear to have passed unnoticed by many at the meeting:1.       D:A:D is a prospective study;2.       all MI endpoints are prospectively validated and generally within 2 months of occurrence; 3.       The duration of follow-up is longer in D:A:D;4.       The mean duration of ART is longer in D:A:D, as is the proportion of patients who had received combination ART;5.       D:A:D is a closed cohort, whereas the VA database continually enrolls patients; and6.       D:A:D has been able to record complete risk factor data (except for HDL cholesterol). Whether these differences explain the differences between the studies is unknown of course. Reassuringly, both studies will have ongoing data collection for at least another 2 years. Analysis of the Johns Hopkins CohortRetrospective analysis of the John Hopkins cohort provided similar conclusions (abstract 132). The authors reported a case-control analysis of the 2672patients enrolled (mean follow-up about 3 years, although the cohort is 12 years old, suggesting substantial ongoing enrolment and/or loss to follow-up). The MI event rate was 10.5/1000 person years of follow-up, compared with population event rates of 2 to 2.5/1000 (and 3 to 3.5/1000 for stroke). Factors independently associated with having had a MI were increasing age, hypertension, hypercholesterolaemia and, most surprisingly, use of d4T (use of PI therapy was associated on univariate analysis, but not multivariate analysis). Test of Carotid Artery Intima ThicknessA prospective study (abstract 139lb) found that carotid artery intima media thickness (a known corollary of atherosclerosis) was greater at baseline in patients who were older, had higher LDL-cholesterol, hypertension and nadir CD4 less than 200. After 1 year, thickness was accelerated by PI therapy and in those with greater age. This begs the question of whether such a tool could be used to screen those at greatest cardiovascular risk, although variability of the technique as well as predictive value of the test needs evaluation in larger samples at multiple sites.

Bone Disease Study of Vitamin D, Calcium Carbonate and AledronateTebas and colleagues (abstract 135) presented results of a phase 2 study exploring the activity of vitamin D (400 IU daily), calcium carbonate (1000 mg daily) and aledronate 70 mg weekly or placebo. Subjects (n=31) were included who had received at least 6 months ART, and who had osteopenia (t-score of less than -1; ie bone mineral density at least 1 standard deviation below mean bone mineral density in adults of the same age and sex). The study was powered to detect a 3% change in spine bone mineral density at 48 weeks. Of the 31 subjects, 87% were male, 29% smokers and 16% moderate drinkers. Their mean t scores in the spine and hip were -1.5 and -1.0, respectively. After 48 weeks, the placebo had no significant improvement in BMD overall or in the hip or femur, although markers of bone turnover (eg. bone alkaline phosphatase) improved. In contrast, spine BMD improved by 3.8%, a 5.2% difference between the 2 groups. Aledronate had no significant effects on BMD elsewhere. This is perhaps not surprising, as spine bone normally turns over more rapidly than does femoral bone. The question remains whether the osteoporosis being treated was HIV or ART-related, and whether aledronate would also be beneficial in adults with osteoporosis (t-score less than -2.5), the group for which aledronate generally offers greatest benefit. A larger ACTG study will commence shortly.

Neurotoxicity Sleep Patterns in Patients Using EfavirenzTwo presentations reported on sleep patterns in patients receiving efavirenz (abstracts 715 and 716). Both found that efavirenz disrupts REM sleep, particularly in those that reported poor sleep prior to efavirenz therapy. REM (restorative) sleep comprised 10% of total sleep in efavirenz recipients versus 22% in non-recipients, although the total duration of sleep was not affected with efavirenz. Loss of REM sleep correlated with reports of insomnia and morning fatigue. Clearly, sleep patterns need proper clinical assessment in patients receiving efavirenz. 02/26/03© Copyright 2003 by HIV and Hepatitis.com. All Rights Reserved.
Reproduction of articles for personal or educational use is encouraged and does not require permission from the publisher. Permission to re-print copyrighted articles is almost always granted, but does require written permission from the publisher (email publisher@...)
   




Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health































































































#2137 From: PoWeRTX@...
Date: Wed Feb 26, 2003 1:36 am
Subject: Switching to Indinavir/Ritonavir and Efavirenz after Failing NRTI Combination Th
PoWeRTX@...
Send Email Send Email
 
Switching to Indinavir/Ritonavir and Efavirenz after Failing NRTI Combination Therapy Improves Lipoatrophy but Increases Lipo-accumulation'
Both protease inhibitors (PI) and nucleosides (NRTI) are believed to contribute to the pathogenesis of HIV-related lipodystrophy syndrome (HIVLD). The role of non-nucleoside analogues (NNRTIs) in HIVLD has not been demonstrated. In the current study (a prospective, 48-week observational sub-study of HIV-NAT 009), researchers evaluated the effect on HIVLD of ceasing combination NRTI therapy and switching to a ritonavir-boosted PI and NNRTI. Patients switched to indinavir/ritonavir 800/100 mg BID and efavirenz 600 mg QD after failing their nucleoside combination therapy.

HIVLD was assessed by a standardized questionnaire, physical examination, fasted laboratory measurements, DEXA scan, and CT scan of mid-abdomen and thigh at weeks 0 and 48. Results were compared by Student's t-test. The study enrolled 61 patients (38 male, 23 female). The median duration of prior NRTI therapy was 4.1 years. Strong correlation between patient and physician based assessments was seen All the correlation coefficients were statistically significant.
Conclusions: The results suggest that ceasing NRTIs and switching to a PI and NNRTI regimen leads to an improvement of lipoatrophy (fat loss). This is consistent with the hypothesis that lipoatrophy is predominantly mediated through NRTI. In addition, the observed concomitant increases in central abdominal fat support the hypothesis that PIs, through a separate mechanism, may lead to lipo-accumulation (fat accumulation).

Study Parameter, Mean (SD) Week 0(n = 60) Week 48(n = 60)
Change

p-value
Weight (kg) 56.6 [9.7] 56.5 [10.5] -0.1 [4.0] 0.25
HIV RNA (c/ml) 15,528 [13,918] 1,564 [7,750] -13,964 [14,907] *
CD4+ 176 [126] 297 [136] 121 [108] *
Lactate (mmol/L) 1.41 [0.74] 1.62 [0.64] 0.20 [0.97] 0.11
Total Cholesterol (mg/dl) 172.2 [36.7] 265.3 [74.6] 93.2 [60.9] *
Triglycerides (mg/dl) 147.3 [83.6] 383.8 [247.5] 236.5 [212.7] *
Glucose (mg/dl) 91.8 [11.5] 94.8 [12.0] 3.1 [13] 0.07
Body Composition, sq. cm. (CT)
Mid-abdomen (visceral fat) 86.3 [49.7] 94.2 [54.3] 8.0 [30.8] 0.05
Mid-abdomen (subcutaneous fat) 95.8 [51.0] 104.5 [54.1] 8.6 [31.7] 0.04
Mid-thigh (subcutaneous fat) 33.1 [23.9] 36.6 [25.3] 3.5 [7.6] *
Body Fat as % of Mass (DEXA)
Fat in trunk 21 [7.0] 22.8 [6.8] 1.8 [3.6] *
Fat in legs 17.5 [9.8] 19.2 [10.0] 1.7 [2.5] *
Fat in arms 18.2 [8.9] 21.0 [10.1] 2.8 [3.8] *
Body Lean as % of Mass (DEXA)
Lean in trunk 77.1 [6.9] 75.4 [6.7] -1.7 [3.6] *
Lean in legs 78.4 [9.3] 76.7 [9.6] -1.7 [3.6] *
Lean in arms 77.1 [8.6] 73.8 [11.3] -3.4 [6.0] *
Patient Assessment of body –3 to +3
Abdomen score (p-value) 0.33 [1.34] (0.12) 1.49 [1.60] (*) 1.15 [1.72] *
Thighs score (p-value) -0.68 [1.28] (*) -0.88 [1.32] (*) -0.20 [1.37] 0.26
Arms score (p-value) -0.88 [1.33] (*) -1.07 [1.49] (*) -0.18 [1.53] 0.36
* p < 0.00102/26/03
Reference
M Boyd and others. Lipodystrophy in Patients Switched to Indinavir/Ritonavir 800/100 mg BID and Efavirenz 600 mg QD after Failing Nucleoside Combination Therapy: A Prospective, 48-week Observational Sub-study of HIV-NAT 009. Abstract 738 (poster).  





Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health






































































































































































































































#2136 From: PoWeRTX@...
Date: Wed Feb 26, 2003 1:26 am
Subject: Protease Inhibitors Linked to Increased Stroke Risk
PoWeRTX@...
Send Email Send Email
 
Protease Inhibitors Linked to Increased Stroke Risk

By Martha Kerr

HIV-infected patients with lipodystrophy syndrome associated with prolonged protease inhibitor use exhibit increased intimal-medial thickening of the carotid arteries, suggesting an increased risk of stroke, University of Miami researchers reported here last week at the American Stroke Association's 28th International Stroke Conference.

Findings from another study, also reported last week at the 10th Conference on Retroviruses and Opportunistic Diseases, indicate that antiretroviral treatment is linked to an increased risk of myocardial infarction. Dr. Mauricio Concha and colleagues reported findings on 21 subjects with HIV infection and lipodystrophy syndrome after long-term exposure to protease inhibitor therapy. These patients were compared with 17 HIV-infected subjects without lipodystrophy and no history of exposure to protease inhibitors.There were no significant differences in the two groups in gender, race, blood pressure, history of diabetes, hyperlipidemia, CD4 cell count, smoking and drug or alcohol use. The study group was older (mean age 47 compared with 41 for control group) and had higher viral load, cholesterol:HDL ratios, triglycerides, insulin, homocysteine, C-reactive protein levels and body mass index.All subjects underwent carotid duplex studies with intimal-medial thickening analyses and transcranial Doppler with vasomotor CO2 reactivity studies.Patients with lipodystrophy syndrome had significantly more atherosclerotic plaques (68%) than did controls (15%). Intimal-medial thickening greater than 1 mm in the common and the internal carotid arteries was more prevalent in the study group (90%) compared with controls (39%).Abnormal vasomotor reactivity was found in 56% of subjects and 27% of controls.Dr. Concha noted that protease inhibitor-induced lipodystrophy syndrome is a relatively new phenomenon and that few outcome data are available. "This lipodystrophy syndrome is beyond just lipodystrophy," he said.He told Reuters Health that intuition tells him to assume the findings indicate an increased risk of stroke among this patients, and that "it makes sense at this point to treat them aggressively."However, "it is important to bear in mind that there is a potential interaction between protease inhibitors and statins," he added. Both are metabolized through the cytochrome P450 pathway.As HIV infection becomes more of a chronic rather than an acute disease, there will be more interactions between the infection, its treatment and the diseases of aging, Dr. Concha said. "It will be months to years before we see the endpoint [of HIV treatment on stroke risk]. In the meantime, aggressive management of risk factors is logical."02/24/03





Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health
























#2135 From: PoWeRTX@...
Date: Tue Feb 25, 2003 8:53 pm
Subject: Re: [lipodystrophy] Bodybuilding - Energy Loss on Meds
PoWeRTX@...
Send Email Send Email
 
In a message dated 2/25/03 9:57:56 AM Central Standard Time, carl@... writes:

I started meds 3 months ago (combivir and viread) and have  since lost my energy and stamina during workouts.  After a couple of reps on any exercise I feel like I've been working out for hours.  I sleep a lot more and I feel almost like I did when I was recovering from hepatitis.   I'm 43 and  have worked out regularly since I was in college and have had periods when I was really energetic and into working out and periods when I wasn't, so I'm not certain that it is the meds.  So far, my blood work is in within normal bounds as is testosterone and thyroid.  It's also the dead of winter in Chicago and that could be contributing to it, but then again maybe not.  I've been reading about mitochondrial toxicity and the effects it has on energy production, but also read that the drugs I'm taking aren't major offenders. 

Anyone else having similar experiences?
 
Carl


Carl: Some people feel very tired when they start AZT. Sometimes it gets better, sometimes it does not. There are several things you may want to do. I have low energy problems a lot. I take DHEA at 50 mg/day and B-12 shots at 1 cc a week and that really helps me. I also take SuperNutrition Energy Caps.

Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health


#2134 From: PoWeRTX@...
Date: Tue Feb 25, 2003 8:38 pm
Subject: Different Antihypertensive Agents Effective at Different Times of Day
PoWeRTX@...
Send Email Send Email
 
Different Antihypertensive Agents Effective at Different Times of Day


It is a well-known tenet of good medical practice that patients with hypertension will probably need a combination of drugs of different classes for effective treatment. The most recent evidence of this was seen in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT), in which 63% of the patients enrolled were on 2 or more drugs by the end of the study.[1] Now a possible explanation for why multiple drug therapy is so often necessary to control hypertension has come from a small study in which different classes of drugs were shown to work most effectively at different times of the day.[2]Researchers from the University of Melbourne, Australia, studied the antihypertensive effects of a beta-blocker, an angiotensin-converting enzyme (ACE) inhibitor, a CCB, and a diuretic in previously untreated patients aged > 65 years with systolic blood pressure (SBP) > 150 mm Hg. Twenty-four patients were randomized in a double-blind, balanced design to atenolol 25 mg, perindopril 4 mg, felodipine 5 mg, hydrochlorothiazide 20 mg, or placebo for 4 weeks. They were then force titrated to double dose, unless contraindicated, and after 1 month at the higher dose, crossed over to the next drug. In total, each patient received 5 treatment regimens over 8 weeks.Ambulatory blood pressure monitoring (ABPM) was done over 1 hour at monthly visits (clinic SBP) and over 25-26 hours at the end of each 2-month drug treatment period (24-hour mean SBP); pressures were recorded during 3 periods of the day: morning (6:00 AM-9:00 AM), awake (9:00 AM-10:00 PM), and sleep (12:00 AM-6:00 AM). Medication was taken at 9:00 AM.All 4 classes of drugs significantly lowered clinic SBP (P < .05) and 24-hour mean SBP (P < .05), although the reductions in SBP were greater with the felodipine and hydrochlorothiazide, confirming the results of a larger study performed by the same investigators with the same drugs.[3] However, hydrochlorothiazide and felodipine had a relatively consistent effect on blood pressure compared with the effects of atenolol and perindopril, which were highly dependent on the time of day. Atenolol was more effective during the awake hours, but had no significant effect during the sleep or morning periods. By contrast, perindopril lowered blood pressure more during sleep hours than awake hours, when it was relatively ineffective. The fall in sleep blood pressure produced by perindopril was, however, greater than with the other drugs.Noting the importance of sleep blood pressure in determining whether end-organ damage, particularly cardiac hypertrophy, occurs, lead researcher Professor Trefor Morgan, MD, suggested that the failure of atenolol to reduce sleep blood pressure might explain why beta-blockers are relatively ineffective at reducing cardiac hypertrophy[4] and in preventing cardiac morbidity and mortality when used as monotherapy for hypertension.[5,6] He also suggested that the greater effectiveness of perindopril during the night might partly explain why ACE inhibitors are so effective in reducing cardiac hypertrophy[4] and deaths due to coronary artery disease, as demonstrated in the Heart Outcomes Prevention Evaluation (HOPE) trial.[7]




Nelson Vergel
Program for Wellness Restoration, PoWeR
An All Volunteer Non-Profit 501 (c) 3 Corporation
Don't Lose Your Body to HIV, click here
Facial Reconstructive Procedures

Click to subscribe to lipodystrophy

"A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses".
Hippocrates (460 BC - 377 BC), Regimen in Health














Messages 2134 - 2163 of 31345   Newest  |  < Newer  |  Older >  |  Oldest
Advanced
Add to My Yahoo!      XML What's This?

Copyright © 2009 Yahoo! Inc. All rights reserved.
Privacy Policy - Terms of Service - Guidelines - Help